Payment overview · 2025
General Payments
$141.13
7 reported records · 5 companies
Healthcare provider profile · identity verified
William E Hopkins, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FINDLAY, OH · NPI 1902869217
Verified facts
What the public records show
CMS Open Payments records show William E Hopkins, M.D. received $141.13 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.65 | 35.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.00 | 24.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $27.19 | 19.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.69 | 11.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.60 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $141.13 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 677 | 193 |
| Lisinopril | Lisinopril | 607 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 280 | 75 |
| Omeprazole | Omeprazole | 271 | 83 |
| Losartan Potassium | Losartan Potassium | 263 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 81 |
| Metformin Hcl | Metformin Hcl | 255 | 73 |
| Simvastatin | Simvastatin | 243 | 64 |
| Glimepiride | Glimepiride | 226 | 58 |
| Gabapentin | Gabapentin | 216 | 53 |
| Sertraline Hcl | Sertraline Hcl | 195 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 51 |
| Furosemide | Furosemide | 159 | 49 |
| Eliquis | Apixaban | 133 | 28 |
| Alendronate Sodium | Alendronate Sodium | 115 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 114 | 29 |
| Allopurinol | Allopurinol | 108 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 26 |
| Potassium Chloride | Potassium Chloride | 98 | 33 |
| Ezetimibe | Ezetimibe | 97 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 27 |
| Trazodone Hcl | Trazodone Hcl | 81 | 18 |
| Alprazolam | Alprazolam | 80 | suppressed |
| Atenolol | Atenolol | 78 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 26 |
| Bupropion Xl | Bupropion Hcl | 68 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Spironolactone | Spironolactone | 68 | 20 |
| Carvedilol | Carvedilol | 67 | 23 |
| Naproxen | Naproxen | 67 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 17 |
| Montelukast Sodium | Montelukast Sodium | 65 | 23 |
| Finasteride | Finasteride | 64 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 15 |
| Amoxicillin | Amoxicillin | 62 | 56 |
| Irbesartan | Irbesartan | 61 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Famotidine | Famotidine | 55 | 21 |
| Acarbose | Acarbose | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 20 |
| Jardiance | Empagliflozin | 52 | 14 |
| Prednisone | Prednisone | 52 | 43 |
| Klor-Con M20 | Potassium Chloride | 51 | 17 |
| Januvia | Sitagliptin Phosphate | 49 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 43 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | 11 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 43 | 14 |
| Synthroid | Levothyroxine Sodium | 41 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 12 |
| Meloxicam | Meloxicam | 39 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 13 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $141.13 · 7 records | PFIZER INC. | COMIRNATY, ELIQUIS, Fluad, Flucelvax, NURTEC ODT, PENBRAYA, PREVNAR 20, QULIPTA, TRUMENBA, UBRELVY, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error